OBJECTIVES: Developing vaccines involves high risk, with most candidates failing before market authorization despite substantial investments. Systemic problems in vaccine product innovation lie at the root of what is called an 'implementation gap'. Additionally, vaccines are being undervalued in many of the current health technology assessment (HTA) processes, leading to underutilization and reduced incentives for innovation among manufacturers. This prompts the necessity for greater cross-sectoral stakeholder alignment to address uncertainties in vaccine research and development (R&D). Therefore, this study devises a methodological framework for Dynamic Vaccine Valuation (DVV) to assess the full value of vaccines in the early vaccine development stages while also promoting cross-sectoral collaboration. The purpose of this study is to present a methodological framework in alignment with the theoretical underpinnings of the Full Value of Vaccines Assessment framework (Hutubessy et al., 2023) and discuss its implications for dynamic simulation modeling.

METHODS: The study synthesized primary and secondary data from an integrative literature review complemented by expert interviews conducted in 2023. Scholarly insights and stakeholder perspectives were integrated to offer a practical methodological pathway towards dynamic simulation modeling.

RESULTS: The DVV framework streamlines vaccine R&D and implementation by employing an early HTA in which product attributes are connected to the implementation system. It assesses vaccines holistically, capturing societal and indirect economic impacts alongside health benefits. Hence, it challenges the status quo on how we assign economic value to vaccines. The DVV framework addresses the need to integrate broader benefits into the value assessment of vaccines. It does so by focusing on stakeholder-centricity, diverse evaluation perspectives, the capacity to adapt to evolving evidence, and transparency, all of which enable continuous learning and adaptability of strategic policy decisions.

CONCLUSIONS: Ultimately, the DVV framework improves trust and consensus between industry and public sector stakeholders, leading to enhanced sustainability and effectiveness of the vaccine development ecosystem.